Temple University

This Week in PNAS

In PNAS this week: effector proteins contributing to Legionnaires' disease virulence, proteomic analysis of transition to quiescence, and more.

The study will use NantHealth's GPS Cancer test to help treat adult and pediatric brain cancer patients.

Two recent studies confirm that CRISPR/Cas9 can edit and inhibit latent HIV provirus, but one of them hints that the virus can develop resistance to excision.

Researchers saw higher-than-anticipated genetic diversity when they sequenced a handful of Plasmodium vivax isolates from a malaria endemic region in Colombia.

The cancer genetic non-profit has opened a new facility located at Temple University.

In the first phase of the three-part pilot program, three projects will be chosen from 10 institutions in the Philadelphia region, Delaware, and New Jersey to receive one-year grants worth as much as $200,000 for proof-of-concept studies.

News Briefs

Premium

Cerenis, Montreal Heart Institute, UVA, Ortho Clinical, Mirna, UCSF, Case Western, Diagnostic Hybrids, iBridge Network, Ben Franklin Tech Partners, and more…

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.